Summary
1H revenue was JPY 262.5B and operating income was JPY 60.1B, both record highs for a first half. Electronics drove the growth on AI demand and pricing gains. The company raised full-year guidance and lifted its FY27 operating income target by JPY 15.0B. It also approved additional investment to fill the remaining just-under-half of Gama Cell6 with EMIB capacity for CPUs, and plans to disclose its approach to Cell7 and Cell9 during FY26. Management noted that the FY30 plan of JPY 1T in revenue and JPY 300B in operating income excludes this new investment, leaving room for upside.
Key Points (Earnings Takeaways and Growth Initiatives)
- Management Strategy and Market View
- Management highlighted a structural shift as AI workloads move from training to inference and agentic AI, which raises CPU content per system.
- It expects the AI GPU/ASIC market to grow at a CAGR of ~20%, and AI-related CPUs at a CAGR above 20%.
- From CY26 to CY30, it estimates SAP demand will rise 5.4x for AI GPUs/ASICs and 2.5x for CPUs. The company's domestic capacity will only double over the same period, so supply should stay tight.
- Management sees no alternative technology that can fill the capacity gap. In its view, the only way to close the supply-demand gap is demand curtailment.
- Current Business Progress and Drivers
- Pricing gains and strong AI demand are driving Electronics. Its 2H OPM is expected to approach 30%.
- The 1H beat in Ceramics was a one-off. It reflected higher-than-usual orders for backup components on certain products, including DPFs.
- 2H Ceramics guidance assumes continued auto-sector weakness, with operating income shrinking to JPY 2.1B.
- EMIB-T ramp-up is on schedule. However, management openly acknowledged it is struggling to improve yields.
- Key Strategic Initiatives and Inflection Points
- Just over half of Gama Cell6 is allocated to EMIB-T. Under an agreement with the customer, the remaining just-under-half will go to EMIB, with the goal of running Cell6 at full capacity.
- Cell7 and Cell9 are under discussion with customers. They will be similar in scale to Cell6 and Cell8, though land constraints mean somewhat smaller floor space.
- The SAP capacity index now covers only high-performance products made in Japan and excludes PC capacity. Management said the change avoids misinterpretation.
- IBIDEN carried out a 2-for-1 stock split and raised the interim dividend to JPY 10.0. It reaffirmed its progressive dividend policy through FY30.
Outlook and Strategy
- Full-year guidance was raised to revenue of JPY 565.0B (+36%), operating income of JPY 133.0B (+114%), and net income of JPY 89.0B. The 2H FX assumption is JPY 150/USD.
- FY27 revenue guidance stays at JPY 650.0B, while operating income was raised to JPY 165.0B. The plan is conservative: it factors in unit price pressure and does not simply extrapolate this year's beat.
- The FY30 plan is unchanged. Potential upside comes from the additional Cell6 capacity and use of the remaining Cell8 floor space. Contributions from Cell7 and Cell9 are expected from FY30 onward.
- Management plans to present a revised FY30 plan during FY26, once the remaining uncertainties are resolved.
- Capex is projected at JPY 210B in FY26 and JPY 350B in FY27, and is expected to stay above JPY 400B in FY28.
- R&D spending is targeted at 6–7% of revenue, with JPY 37B planned for FY26. Nuclear-grade graphite (FGM) is positioned as a potential core business from FY30 onward.
Positive Factors
- Better product mix and a shift toward higher value-added products should lift Electronics OPM to ~35% by FY30.
- Electronics EBITDA margin is planned at 47.6% in FY26 and 48.3% in FY27. Management expects it to exceed 50% from FY28 and approach 60%.
- In current pricing negotiations, securing capacity is the top customer priority. Management expects supplier leverage to persist into next year.
- The supply base for leading-edge AI products is moving to three vendors. Even so, combined competitor capacity still falls short of demand, so management sees IBIDEN's share and positioning as intact.
- The additional investment targets an asset turnover of ~1x, with revenue roughly equal to capex. OPM is expected to exceed 30%, in line with existing high-performance products.
- Growing substrate complexity should keep raising value-add. Drivers include embedded components in the core, multi-core designs, and future glass cores.
Concerns and Risks
- EMIB-T yields are a challenge across the industry. The biggest hurdle is forming electrical connections on the back side of the bridge chip.
- Unit price declines are expected from FY27. The durability of pricing power is a key assumption in the profit plan that warrants scrutiny.
- Lead times for some equipment have lengthened, which would raise procurement risk if Cell7 and Cell9 go ahead.
- Talent to support ramp-ups is a bottleneck. New plants will be brought online in phases, and it takes at least ~4 years from decision to volume production.
- FY27 D&A is limited to JPY 90B as construction-in-progress builds up. Investment is front-loaded, with returns concentrated from FY28 onward.
- The 2H FX assumption of JPY 150/USD compares with an actual 1H rate of JPY 159/USD. Ceramics results could also swing with auto market conditions.
Performance Highlights
1H revenue was JPY 262.5B (+34% YoY), operating income was JPY 60.1B (+85% YoY), and net income was JPY 38.6B (+75% YoY). All three beat the plan disclosed on Aug 4 (revenue of JPY 253.5B, operating income of JPY 54.5B). Electronics contributed 83% of operating income (our estimate), and every segment posted profit growth.
Segment Performance
| Segment | Revenue | YoY | Operating Income | YoY |
|---|---|---|---|---|
| Electronics | JPY 172.5B | +52% | JPY 50.0B | +97% |
| Ceramics | JPY 46.2B | +16% | JPY 5.4B | +40% |
| Other | JPY 43.8B | +4% | JPY 4.7B | +42% |
| Consolidated Total | JPY 262.5B | +34% | JPY 60.1B | +85% |
- Operating Income Margin: 22.9% (+6.2pt from 16.7% in the prior-year period)
- Net Income Margin: 14.7% (+3.4pt from 11.3% in the prior-year period)
- Actual FX Rate: JPY 159/USD (JPY 145/USD in the prior-year period)
- Interim Dividend: JPY 10.0/share (+JPY 2.5 vs. the FY25 year-end dividend of JPY 7.5, split-adjusted)
- Full-Year Electronics OPM Outlook: 29.6% (our estimate)
Q&A List
Q&A not disclosed per company policy
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

